Eli Lilly was mentioned as a competitor to Novo Nordisk in terms of R&D spending as a percentage of revenue.
Source Post
Novo Nordisk Gives Uninspiring Outlook
Sep 26, 2026
Novo Nordisk's stock has fallen over 25% year-to-date following an uninspiring revenue outlook of mid-single-digit growth through 2030. Despite serving over 60 million patients, investors are disappointed by the slower growth compared to previous years, attributed partly to patent expirations and a decline in return on invested capital. The company is trading at a historically low forward P/E ratio, and the analyst's fair value estimate is $64.50, significantly above the current market price of $38.36.
Linked Mentions
Tickers discussed in this post
Pfizer was mentioned as a competitor to Novo Nordisk in terms of R&D spending as a percentage of revenue.
Novo Nordisk is trading at a historically low valuation, with its fair value estimated at $64.50 compared to the current market price of $38.36, despite an uninspiring outlook.
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.